Compare AstraZeneca plc (AZN) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Vale SA — how do they compare? AstraZeneca plc trades at $167 (market cap $253.13B), while Vale SA trades at $14.57 (market cap $60.78B). The key difference: AstraZeneca plc is far larger — about 4.2× Vale SA's market cap, and Vale SA pays the higher dividend (8.63%). Which is the better fit depends on your goals.
| AZN | VALE | |
|---|---|---|
Market Cap | $253.13B | $60.78B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $17.82 |
52-Week Low | $137.44 | $9.53 |
Enterprise Value | $279.37B | $77.70B |
Dividend Yield | 1.92% | 8.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
VALE trades at $14.18, down 1.94% for the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $38.40B in 2025 with a net income margin of 7.21%, while recent news highlights a $2.6B decarbonization investment and governance developments. Cash flow remains positive, with operating cash flow at $8.80B in 2025.
The outlook is cautious; while analyst consensus is a Buy with a $17.50 price target, fundamental pressures from declining profit margins and a high debt-to-asset ratio of 24.66% pose risks. Upside depends on commodity price stability and execution of strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
